| Sep 3 |
Senti Bio to Participate in Upcoming Investor Conferences
|
| Aug 14 |
Senti Biosciences GAAP EPS of -$2.45
|
| Aug 13 |
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
|
| Aug 5 |
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
|
| Jul 16 |
Senti Biosciences to effect 1-for-10 reverse stock split for Nasdaq compliance
|
| Jul 16 |
Senti Bio Announces Reverse Stock Split
|
| Jul 1 |
Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
|
| Jul 1 |
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
|
| May 13 |
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
|
| May 10 |
Senti Biosciences GAAP EPS of -$0.26
|
